Trial Profile
A Single-Center, Open-Label Study to Evaluate the Renal Function Improvement in Lamivudine Long Term Used HBsAg Positive Kidney Transplantation Patients After Switch to Telbivudine Treatment.
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 24 Sep 2016
Price :
$35
*
At a glance
- Drugs Telbivudine (Primary) ; Lamivudine
- Indications Hepatitis B; Kidney disorders
- Focus Therapeutic Use
- 24 Sep 2016 New trial record